Kopran Limited (NSE:KOPRAN)
India · Delayed Price · Currency is INR 125.00
+5.02 (4.18%)
Apr 6, 2026, 3:29 PM IST
Kopran Revenue
Kopran had revenue of 1.94B INR in the quarter ending December 31, 2025, with 16.87% growth. This brings the company's revenue in the last twelve months to 6.20B, down -3.66% year-over-year. In the fiscal year ending March 31, 2025, Kopran had annual revenue of 6.30B with 2.44% growth.
Revenue (ttm)
6.20B
Revenue Growth
-3.66%
P/S Ratio
0.98
Revenue / Employee
6.05M
Employees
1,024
Market Cap
6.05B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 6.30B | 150.13M | 2.44% |
| Mar 31, 2024 | 6.15B | 636.05M | 11.54% |
| Mar 31, 2023 | 5.51B | 734.66M | 15.38% |
| Mar 31, 2022 | 4.78B | -142.93M | -2.91% |
| Mar 31, 2021 | 4.92B | 1.32B | 36.81% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 568.09B |
| Cipla | 279.67B |
| Apollo Hospitals Enterprise | 242.15B |
| Divi's Laboratories | 103.14B |
| Remus Pharmaceuticals | 7.48B |
| Sigachi Industries | 4.85B |
| Accent Microcell | 2.78B |
| Max India | 1.84B |